相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
Richard F. Schlenk et al.
ANNALS OF HEMATOLOGY (2016)
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Marie-Luise Huetter-Kroenke et al.
HAEMATOLOGICA (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Marie-Luise Huetter-Kroenke et al.
HAEMATOLOGICA (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2015)
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Alan K. Burnett et al.
BLOOD (2015)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Peter Paschka et al.
HAEMATOLOGICA (2015)
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi et al.
LANCET ONCOLOGY (2015)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Peter Paschka et al.
HAEMATOLOGICA (2015)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Michela Tassara et al.
BLOOD (2014)
Gemtuzumab ozogamicin in acute myeloid leukemia revisited
Felicitas Thol et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Gail J. Roboz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
Roelof Willemze et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG
M. Fiegl et al.
LEUKEMIA (2014)
Clinical potential of elacytarabine in patients with acute myeloid leukemia
Lindsay A. M. Rein et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse
Tim Pfeiffer et al.
HAEMATOLOGICA (2013)
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older
Claude Gardin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia
Steven Trifilio et al.
LEUKEMIA RESEARCH (2013)
Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-Combined Prospective Analysis by the German AML Intergroup
Thomas Buechner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
Stefan Faderl et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
Je-Hwan Lee et al.
BLOOD (2011)
Primary refractory acute myeloid leukaemia - in search of better definitions and therapies
Farhad Ravandi
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Alan K. Burnett et al.
BLOOD (2010)
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
Farhad Ravandi et al.
BLOOD (2010)
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
Cecile Pautas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXomeA®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients
Andrea Camera et al.
ANNALS OF HEMATOLOGY (2009)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
Stefan Froehling et al.
BLOOD (2006)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia - Review of three randomized trials
Wolfgang Kern et al.
CANCER (2006)
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Donald W. Milligan et al.
BLOOD (2006)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
RF Schlenk et al.
LEUKEMIA (2004)
Risk-adapted postremission therapy in acute myeloid leukemia:: results of the German multicenter AML HD93 treatment trial
RF Schlenk et al.
LEUKEMIA (2003)
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
W Kern et al.
BLOOD (2003)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation
G Jackson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
